-
[18F]AlF-CBP imaging of type I collagen for non-invasive monitoring of pulmonary fibrosis in preclinical models Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2024-08-22 Yang Liu, Peipei Tang, Simin Peng, Jinmei Zhong, Zexin Xu, Jiawei Zhong, Jin Su, Yuhua Zhong, Kongzhen Hu
-
Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent 177Lu-Labeled Radiohapten J Nucl. Med. (IF 9.1) Pub Date : 2024-08-21 Brett A. Vaughn, Sang-gyu Lee, Daniela Burnes Vargas, Shin Seo, Sara S. Rinne, Hong Xu, Hong-fen Guo, Alexandre B. Le Roux, Leah Gajecki, Simone Krebs, Guangbin Yang, Ouathek Ouerfelli, Pat B. Zanzonico, Edward K. Fung, Samantha St. Jean, Sebastian E. Carrasco, Achim Jungbluth, Nai Kong V. Cheung, Steven M. Larson, Darren R. Veach, Sarah M. Cheal
Radiolabeled small-molecule DOTA-haptens can be combined with antitumor/anti-DOTA bispecific antibodies (BsAbs) for pretargeted radioimmunotherapy (PRIT). For optimized delivery of the theranostic γ- and β-emitting isotope 177Lu with DOTA-based PRIT (DOTA-PRIT), bivalent Gemini (DOTA-Bn-thiourea-PEG4-thiourea-Bn-DOTA, aka (3,6,9,12-tetraoxatetradecane-1,14-diyl)bis(DOTA-benzyl thiourea)) was developed
-
Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study J Nucl. Med. (IF 9.1) Pub Date : 2024-08-21 Pan Thin, Masatoshi Hotta, Andrei Gafita, Tristan Grogan, Johannes Czernin, Jeremie Calais, Ida Sonni
This analysis aimed to identify clinical factors associated with positivity on repeat 68Ga-PSMA-11 PET/CT after a negative scan in patients with recurrent prostate cancer (PCa) under observation. Methods: This single-center, retrospective analysis included patients who underwent at least 2 68Ga-PSMA-11 PET/CT scans (PET1 and PET2) at UCLA between October 2016 and June 2021 for recurrent PCa with negative
-
Multi-Scale Spatial-Temporal Attention Networks for Functional Connectome Classification IEEE Trans. Med. Imaging (IF 8.9) Pub Date : 2024-08-22 Youyong Kong, Xiaotong Zhang, Wenhan Wang, Yue Zhou, Yueying Li, Yonggui Yuan
-
Self-Supervised Representation Distribution Learning for Reliable Data Augmentation in Histopathology WSI Classification IEEE Trans. Med. Imaging (IF 8.9) Pub Date : 2024-08-22 Kunming Tang, Zhiguo Jiang, Kun Wu, Jun Shi, Fengying Xie, Wei Wang, Haibo Wu, Yushan Zheng
-
Unsupervised Non-rigid Histological Image Registration Guided by Keypoint Correspondences Based on Learnable Deep Features with Iterative Training IEEE Trans. Med. Imaging (IF 8.9) Pub Date : 2024-08-21 Xingyue Wei, Lin Ge, Lijie Huang, Jianwen Luo, Yan Xu
-
Optimized Excitation in Microwave-induced Thermoacoustic Imaging for Artifact Suppression IEEE Trans. Med. Imaging (IF 8.9) Pub Date : 2024-08-21 Qiang Liu, Weian Chao, Ruyi Wen, Yubin Gong, Lei Xi
-
Moment-Consistent Contrastive CycleGAN for Cross-Domain Pancreatic Image Segmentation IEEE Trans. Med. Imaging (IF 8.9) Pub Date : 2024-08-21 Zhongyu Chen, Yun Bian, Erwei Shen, Ligang Fan, Weifang Zhu, Fei Shi, Chengwei Shao, Xinjian Chen, Dehui Xiang
-
Noninvasive quantification of [18F]SynVesT-1 binding using simplified reference tissue model 2 Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2024-08-19 Mika Naganawa, Jean-Dominique Gallezot, Songye Li, Nabeel B. Nabulsi, Shannan Henry, Zhengxin Cai, David Matuskey, Yiyun Huang, Richard E. Carson
-
Construction and preclinical evaluation of a 124I-labelled bispecific antibody targeting PD-L1 and PD-L2 Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2024-08-19 Yuan Yao, Yanan Ren, Xingguo Hou, Pei Wang, Jinyu Zhu, Song Liu, Xiaokun Ma, Teli Liu, Zhi Yang, Hua Zhu, Nan Li
-
Spatial-temporal dynamic evolution of lewy body dementia by metabolic PET imaging Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2024-08-19 Jiaqi Niu, Yan Zhong, Le Xue, Haotian Wang, Daoyan Hu, Yi Liao, Xiaohui Zhang, Xiaofeng Dou, Congcong Yu, Bo Wang, Yuan Sun, Mei Tian, Hong Zhang, Jing Wang
-
Bridging MRI Cross-Modality Synthesis and Multi-Contrast Super-Resolution by Fine-Grained Difference Learning IEEE Trans. Med. Imaging (IF 8.9) Pub Date : 2024-08-19 Yidan Feng, Sen Deng, Jun Lyu, Jing Cai, Mingqiang Wei, Jing Qin
-
Investigating and Improving Latent Density Segmentation Models for Aleatoric Uncertainty Quantification in Medical Imaging IEEE Trans. Med. Imaging (IF 8.9) Pub Date : 2024-08-19 M. M. Amaan Valiuddin, Christiaan G. A. Viviers, Ruud J. G. Van Sloun, Peter H. N. De With, Fons van der Sommen
-
SISMIK for brain MRI: Deep-learning-based motion estimation and model-based motion correction in k-space IEEE Trans. Med. Imaging (IF 8.9) Pub Date : 2024-08-19 Oscar Dabrowski, Jean-Luc Falcone, Antoine Klauser, Julien Songeon, Michel Kocher, Bastien Chopard, François Lazeyras, Sébastien Courvoisier
-
Development of [177Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2024-08-15 Jianhao Chen, Yizhen Pang, Xiyi Liao, Yangfan Zhou, Qicong Luo, Hua Wu, Changjing Zuo, Jingjing Zhang, Qin Lin, Xiaoyuan Chen, Liang Zhao, Haojun Chen
-
Standardized template for clinical reporting of PSMA PET/CT scans Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2024-08-15 Shadi A. Esfahani, Michael J. Morris, Oliver Sartor, Mark Frydenberg, Stefano Fanti, Jeremie Calais, Neha Vapiwala
-
Quantitative Assessments of Tumor Activity in a General Oncologic PET/CT Population: Which Metric Minimizes Tracer Uptake Time Dependence? J Nucl. Med. (IF 9.1) Pub Date : 2024-08-14 Semra Ince, Richard Laforest, Malak Itani, Vikas Prasad, Paul-Robert Derenoncourt, John P. Crandall, Saeed Ashrafinia, Anne M. Smith, Richard L. Wahl, Tyler J. Fraum
Visual Abstract
-
Theranostic Intratumoral Convection-Enhanced Delivery of 124I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry J Nucl. Med. (IF 9.1) Pub Date : 2024-08-14 Neeta Pandit-Taskar, Pat B. Zanzonico, Milan Grkovski, Maria Donzelli, Scott M. Vietri, Christopher Horan, Brian Serencsits, Kavya Prasad, Serge Lyashchenko, Kim Kramer, Ira J. Dunkel, Mark M. Souweidane
Diffuse intrinsic pontine glioma (DIPG) is a rare childhood malignancy with poor prognosis. There are no effective treatment options other than external beam therapy. We conducted a pilot, first-in-human study using 124I-omburtamab imaging and theranostics as a therapeutic approach using a localized convection-enhanced delivery (CED) technique for administering radiolabeled antibody. We report the
-
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up J Nucl. Med. (IF 9.1) Pub Date : 2024-08-14 Stefano Severi, Ilaria Grassi, Alberto Bongiovanni, Silvia Nicolini, Irene Marini, Donatella Arpa, Nicoletta Ranallo, Irene Azzali, Valentina Di Iorio, Anna Sarnelli, Monti Manuela, Elena Amadori, Lucia Fabbri, Daniela Bartolini, Luigino Tosatto, Francesco Di Meco, Lorena Gurrieri, Nada Riva, Luana Calabro, Federica Matteucci, Giovanni Paganelli, Maddalena Sansovini
Visual Abstract
-
Single Chelator–Minibody Theranostic Agents for 89Zr PET Imaging and 177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer J Nucl. Med. (IF 9.1) Pub Date : 2024-08-14 Khanh-Van Ho, David S. Tatum, Lisa Watkinson, Terry Carmack, Fang Jia, Alessandro Mascioni, Charles A. Maitz, Darren Magda, Carolyn J. Anderson
Here we describe an anti–prostate-specific membrane antigen (PSMA) minibody (IAB2MA) conjugated to an octadentate, macrocyclic chelator based on four 1-hydroxypyridin-2-one coordinating units (Lumi804 [L804]) labeled with 89Zr (PET imaging) and 177Lu (radiopharmaceutical therapy), with the goal of developing safer and more efficacious treatment options for prostate cancer. Methods: L804 was compared
-
Bi-Constraints Diffusion: A Conditional Diffusion Model with Degradation Guidance for Metal Artifact Reduction IEEE Trans. Med. Imaging (IF 8.9) Pub Date : 2024-08-15 Mengting Luo, Nan Zhou, Tao Wang, Linchao He, Wang Wang, Hu Chen, Peixi Liao, Yi Zhang
-
AutoSamp: Autoencoding k-space Sampling via Variational Information Maximization for 3D MRI IEEE Trans. Med. Imaging (IF 8.9) Pub Date : 2024-08-15 Cagan Alkan, Morteza Mardani, Congyu Liao, Zhitao Li, Shreyas S. Vasanawala, John M. Pauly
-
S2Former-OR: Single-Stage Bi-Modal Transformer for Scene Graph Generation in OR IEEE Trans. Med. Imaging (IF 8.9) Pub Date : 2024-08-15 Jialun Pei, Diandian Guo, Jingyang Zhang, Manxi Lin, Yueming Jin, Pheng-Ann Heng
-
Identifying the primary tumour in patients with cancer of unknown primary (CUP) using [18F]FDG PET/CT: a systematic review and individual patient data meta-analysis Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2024-08-14 Jeroen R. J. Willemse, Doenja M. J. Lambregts, Sara Balduzzi, Winnie Schats, Petur Snaebjornsson, Serena Marchetti, Marieke A. Vollebergh, Larissa W. van Golen, Zing Cheung, Wouter V. Vogel, Zuhir Bodalal, Sajjad Rostami, Oke Gerke, Tharani Sivakumaran, Regina G.H. Beets-Tan, Max J. Lahaye
-
Domain-interactive Contrastive Learning and Prototype-guided Self-training for Cross-domain Polyp Segmentation IEEE Trans. Med. Imaging (IF 8.9) Pub Date : 2024-08-14 Ziru Lu, Yizhe Zhang, Yi Zhou, Ye Wu, Tao Zhou
-
Deep learning-aided respiratory motion compensation in PET/CT: addressing motion induced resolution loss, attenuation correction artifacts and PET-CT misalignment Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2024-08-13 Yihuan Lu, Fei Kang, Duo Zhang, Yue Li, Hao Liu, Chen Sun, Hao Zeng, Lei Shi, Yumo Zhao, Jing Wang
-
Enhancing the vision–language foundation model with key semantic knowledge-emphasized report refinement Med. Image Anal. (IF 10.7) Pub Date : 2024-08-13 Weijian Huang, Cheng Li, Hao Yang, Jiarun Liu, Yong Liang, Hairong Zheng, Shanshan Wang
Recently, vision–language representation learning has made remarkable advancements in building up medical foundation models, holding immense potential for transforming the landscape of clinical research and medical care. The underlying hypothesis is that the rich knowledge embedded in radiology reports can effectively assist and guide the learning process, reducing the need for additional labels. However
-
Prompt-driven Latent Domain Generalization for Medical Image Classification IEEE Trans. Med. Imaging (IF 8.9) Pub Date : 2024-08-13 Siyuan Yan, Zhen Yu, Chi Liu, Lie Ju, Dwarikanath Mahapatra, Brigid Betz-Stablein, Victoria Mar, Monika Janda, Peter Soyer, Zongyuan Ge
-
Exploring the value of FAP-targeted PET/CT in differentiating breast cancer molecular subtypes: a preliminary study Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2024-08-12 Tianxin Liu, Shengnan Xu, Kai Cheng, Jinli Pei, Shijie Wang, Chao Li, Wanhu Li, Zhiyong Yu, Jinming Yu, Jie Liu
-
Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2024-08-12 Solfrid Thunold, Eivor Hernes, Saima Farooqi, Åsa Kristina Öjlert, Roslyn J. Francis, Anna K. Nowak, Weronika Maria Szejniuk, Søren Steen Nielsen, Susana Cedres, Marc Simo Perdigo, Jens Benn Sørensen, Carin Meltzer, Lars Tore Gyland Mikalsen, Åslaug Helland, Eirik Malinen, Vilde Drageset Haakensen
-
Diversity matters: Cross-head mutual mean-teaching for semi-supervised medical image segmentation Med. Image Anal. (IF 10.7) Pub Date : 2024-08-10 Wei Li, Ruifeng Bian, Wenyi Zhao, Weijin Xu, Huihua Yang
Semi-supervised medical image segmentation (SSMIS) has witnessed substantial advancements by leveraging limited labeled data and abundant unlabeled data. Nevertheless, existing state-of-the-art (SOTA) methods encounter challenges in accurately predicting labels for the unlabeled data, giving rise to disruptive noise during training and susceptibility to erroneous information overfitting. Moreover,
-
Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy J Nucl. Med. (IF 9.1) Pub Date : 2024-08-08 Surekha Yadav, Blair Lowery, Abuzar Moradi Tuchayi, Fei Jiang, Rachelle Saelee, Rahul R. Aggarwal, Roxanna Juarez, Robert R. Flavell, Thomas A. Hope
177Lu can be imaged after administration using SPECT/CT. Most work to date has focused on using posttreatment imaging to measure normal organ and tumor dose. We aimed to assess the impact of posttreatment SPECT/CT on the management of patients undergoing 177Lu-prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT). Methods: In this retrospective study, 122 patients underwent PSMA
-
Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT J Nucl. Med. (IF 9.1) Pub Date : 2024-08-08 Sherrington Li, Andrew Nguyen, William Counter, Nikeith C. John, Jeremiah De Leon, George Hruby, Anthony M. Joshua, Phillip Stricker, Megan Crumbaker, Narjess Ayati, Lyn Chan, Zahra Sabahi, Mina Swiha, Andrew Kneebone, Keith Wong, Victor Liu, Shikha Sharma, Shikha Agrawal, Louise M. Emmett
Despite a high detection rate of 68Ga-prostate-specific membrane antigen (PSMA) PET/CT in biochemical recurrence (BCR) of prostate cancer, a significant proportion of men have negative 68Ga-PSMA-11 PET/CT results. Gastrin-releasing peptide receptor, targeted by the copper-chelated bombesin analog 64Cu-sarcophagine-bombesin (SAR-BBN) PET/CT, is also overexpressed in prostate cancer. In this prospective
-
[68Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria J Nucl. Med. (IF 9.1) Pub Date : 2024-08-08 Ismini C. Mainta, Angeliki Neroladaki, Nicola Bianchetto Wolf, Daniel Benamran, Sana Boudabbous, Thomas Zilli, Valentina Garibotto
In up to two thirds of prostate-specific membrane antigen (PSMA) PET scans, unspecific bone uptake has been described. The aim of this study was to estimate the diagnostic accuracy of [68Ga]Ga-PSMA-11 PET/CT for bone metastases and the occurrence of equivocal lesions. Methods: We analyzed retrospectively 118 patients who underwent a [68Ga]Ga-PSMA-11 PET/CT for initial staging or recurrence evaluation
-
[99mTc]Tc-hydroxydiphosphonate uptake in soft tissue is associated with amyloid load in subcutaneous abdominal fat tissue and mortality in wild-type transthyretin amyloidosis patients Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2024-08-08 Hendrea Sanne Aletta Tingen, Dion Groothof, Alwin Tubben, Johan Bijzet, Ewout J. Houwerzijl, Friso L. H. Muntinghe, Paul A. van der Zwaag, Peter van der Meer, Bouke P. C. Hazenberg, Riemer H. J. A. Slart, Hans L. A. Nienhuis
-
Loss of synaptic density in nucleus basalis of meynert indicates distinct neurodegeneration in Alzheimer’s disease: the RJNB-D study Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2024-08-08 Binyin Li, Haijuan Chen, Yingting Zheng, Xiaomeng Xu, Zhiwen You, Qi Huang, Yiyun Huang, Yihui Guan, Jun Zhao, Jun Liu, Fang Xie, Jie Wang, Wei Xu, Junfang Zhang, Yulei Deng
-
BrainSegFounder: Towards 3D foundation models for neuroimage segmentation Med. Image Anal. (IF 10.7) Pub Date : 2024-08-08 Joseph Cox, Peng Liu, Skylar E. Stolte, Yunchao Yang, Kang Liu, Kyle B. See, Huiwen Ju, Ruogu Fang
The burgeoning field of brain health research increasingly leverages artificial intelligence (AI) to analyze and interpret neuroimaging data. Medical foundation models have shown promise of superior performance with better sample efficiency. This work introduces a novel approach towards creating 3-dimensional (3D) medical foundation models for multimodal neuroimage segmentation through self-supervised
-
SDF4CHD: Generative modeling of cardiac anatomies with congenital heart defects Med. Image Anal. (IF 10.7) Pub Date : 2024-08-08 Fanwei Kong, Sascha Stocker, Perry S. Choi, Michael Ma, Daniel B. Ennis, Alison L. Marsden
Congenital heart disease (CHD) encompasses a spectrum of cardiovascular structural abnormalities, often requiring customized treatment plans for individual patients. Computational modeling and analysis of these unique cardiac anatomies can improve diagnosis and treatment planning and may ultimately lead to improved outcomes. Deep learning (DL) methods have demonstrated the potential to enable efficient
-
The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2024-08-07 Luca Filippi, Luca Urso, Cristina Ferrari, Priscilla Guglielmo, Laura Evangelista
-
Risk Stratification in Cardiac Sarcoidosis With Cardiac Positron Emission Tomography: A Systematic Review and Meta-Analysis JACC Cardiovasc. Imaging (IF 12.8) Pub Date : 2024-08-07 Tahir S. Kafil MD, Omar M. Shaikh MD, Yehia Fanous MD, Joseph Benjamen MD, Muhammad M. Hashmi MD, Abdulazeez Jawad MD, Tahir Dahrouj MD, Rami M. Abazid MD, Mina Swiha MD, Jonathan Romsa MD, Rob S.B. Beanlands MD, Terrence D. Ruddy MD, Lisa Mielniczuk MD, David H. Birnie MD, Nikolaos Tzemos MD
Although positron emission tomography (PET) imaging is well established for its diagnostic role in cardiac sarcoidosis, less is known about the prognostic value of PET and its use in risk stratification for major adverse cardiac events (MACE). The goal of this study was to perform a systematic review and meta-analysis looking at the prognostic value of PET imaging in patients with cardiac sarcoidosis
-
E[formula omitted]-MIL: An explainable and evidential multiple instance learning framework for whole slide image classification Med. Image Anal. (IF 10.7) Pub Date : 2024-08-06 Jiangbo Shi, Chen Li, Tieliang Gong, Huazhu Fu
Multiple instance learning (MIL)-based methods have been widely adopted to process the whole slide image (WSI) in the field of computational pathology. Due to the sparse slide-level supervision, these methods usually lack good localization on the tumor regions, leading to poor interpretability. Moreover, they lack robust uncertainty estimation of prediction results, leading to poor reliability. To
-
Internal auditory canal tumor presented on [18F]AlF-FAPI-74 and [18F]AlF-PSMA-BCH PET/CT in a prostate cancer patient Eur. J. Nucl. Med. Mol. Imaging (IF 8.6) Pub Date : 2024-08-05 Xin Cheng, Guozhu Hou, Rong Zheng, Xuejuan Wang
-
Performance Characteristics of the NeuroEXPLORER, a Next-Generation Human Brain PET/CT Imager J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Hongdi Li, Ramsey D. Badawi, Simon R. Cherry, Kathryn Fontaine, Liuchun He, Shannan Henry, Ansel T. Hillmer, Lingzhi Hu, Nikkita Khattar, Edwin K. Leung, Tiantian Li, Yusheng Li, Chi Liu, Peng Liu, Zhenrui Lu, Stanislaw Majewski, David Matuskey, Evan D. Morris, Tim Mulnix, Negar Omidvari, Suranjana Samanta, Aaron Selfridge, Xishan Sun, Takuya Toyonaga, Tommaso Volpi, Tianyi Zeng, Terry Jones, Jinyi
The collaboration of Yale, the University of California, Davis, and United Imaging Healthcare has successfully developed the NeuroEXPLORER, a dedicated human brain PET imager with high spatial resolution, high sensitivity, and a built-in 3-dimensional camera for markerless continuous motion tracking. It has high depth-of-interaction and time-of-flight resolutions, along with a 52.4-cm transverse field
-
Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Fei Kang, Zhaojuan Xie, Wenhui Ma, Zhiyong Quan, Guiyu Li, Kun Guo, Xiang Li, Taoqi Ma, Weidong Yang, Yizhang Zhao, Hongyuan Yi, Yumo Zhao, Yihuan Lu, Jing Wang
Brain PET imaging often faces challenges from head motion (HM), which can introduce artifacts and reduce image resolution, crucial in clinical settings for accurate treatment planning, diagnosis, and monitoring. United Imaging Healthcare has developed NeuroFocus, an HM correction (HMC) algorithm for the uMI Panorama PET/CT system, using a data-driven, statistics-based approach. The HMC algorithm automatically
-
RadShap: An Explanation Tool for Highlighting the Contributions of Multiple Regions of Interest to the Prediction of Radiomic Models J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Nicolas Captier, Fanny Orlhac, Narinée Hovhannisyan-Baghdasarian, Marie Luporsi, Nicolas Girard, Irène Buvat
Explaining the decisions made by a radiomic model is of significant interest, as it can provide valuable insights into the information learned by complex models and foster trust in well-performing ones, thereby facilitating their clinical adoption. Promising radiomic approaches that aggregate information from multiple regions within an image currently lack suitable explanation tools that could identify
-
hHEPATO-Cy5, a Bimodal Tracer for Image-Guided Hepatobiliary Surgery J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Daphne D.D. Rietbergen, Tessa Buckle, Leon J. Slof, Maarten P. van Meerbeek, Clarize M. de Korne, Mick M. Welling, Matthias N. van Oosterom, Kevin Bauwens, Meta Roestenberg, Julia Kloetzl, Fijs W.B. van Leeuwen
Liver cancer is a leading cause of cancer deaths worldwide. Surgical resection of superficial hepatic lesions is increasingly guided by the disrupted bile excretion of the fluorescent dye indocyanine green (ICG). To extend this approach to deeper lesions, a dedicated bimodal tracer that facilitates both fluorescence guidance and radioguidance was developed. Methods: A tracer comprising a methylated
-
Noninvasive Diagnostic Method to Objectively Measure Olfaction and Diagnose Smell Disorders by a Molecularly Targeted Fluorescence Imaging Agent J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Dauren Adilbay, Junior Gonzales, Marianna Zazhytska, Paula Demetrio de Souza Franca, Sheryl Roberts, Tara D. Viray, Raik Artschwager, Snehal Patel, Albana Kodra, Jonathan B. Overdevest, Chun Yuen Chow, Glenn F. King, Sanjay K. Jain, Alvaro A. Ordonez, Laurence S. Carroll, Stavros Lomvardas, Thomas Reiner, Nagavarakishore Pillarsetty
Despite the recent advances in understanding the mechanisms of olfaction, no tools are currently available to noninvasively identify loss of smell. Because of the substantial increase in patients presenting with coronavirus disease 2019–related loss of smell, the pandemic has highlighted the urgent need to develop quantitative methods. Methods: Our group investigated the use of a novel fluorescent
-
Performing [18F]MFBG Long–Axial-Field-of-View PET/CT Without Sedation or General Anesthesia for Imaging of Children with Neuroblastoma J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Lise Borgwardt, Jesper Brok, Kim Francis Andersen, Jacob Madsen, Nicholas Gillings, Marie Øbro Fosbøl, Charlotte Lund Denholt, Ida Nymann Petersen, Louise Sørup Sørensen, Lotte Hahn Enevoldsen, Peter Sandor Oturai, Helle Hjort Johannesen, Liselotte Højgaard, Christina Schulze, Eunice Saxtoft, Flemming Andersen, Barbara Malene Fischer
Meta-[123I]iodobenzylguanidine ([123I]MIBG) scintigraphy with SPECT/CT is the standard of care for diagnosing and monitoring neuroblastoma. Replacing [123I]MIBG with the new PET tracer meta-[18F]fluorobenzylguanidine ([18F]MFBG) and further improving sensitivity and reducing noise in a new long-axial-field-of-view (LAFOV) PET/CT scanner enable increased image quality and a faster acquisition time,
-
Factors Associated with Myocardial Uptake on Oncologic Somatostatin PET Investigations and Differentiation from Myocardial Uptake of Acute Myocarditis J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Thomas Larive, Caroline Boursier, Marine Claudin, Jeanne Varlot, Laura Filippetti, Olivier Huttin, Véronique Roch, Laetitia Imbert, Matthieu Doyen, Aurélien Lambert, Damien Mandry, Zohra Lamiral, Elodie Chevalier, Pierre-Yves Marie
Myocardial somatostatin PET uptake is observed not only in most patients with acute myocarditis (AM) but also in some oncology patients referred for routine somatostatin PET. This raises concerns about the specificity of somatostatin PET for detecting myocarditis. The current study aims to identify factors associated with the detection of myocardial uptake on somatostatin PET scans recorded for oncology
-
Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [177Lu]Lu-PSMA-I&T Therapy J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Sandra Resch, Sibylle I. Ziegler, Gabriel Sheikh, Lena M. Unterrainer, Mathias J. Zacherl, Peter Bartenstein, Guido Böning, Julia Brosch-Lenz, Astrid Delker
Internal dosimetry supports safe and effective patient management during radionuclide therapy. Yet, it is associated with high clinical workload, costs, and patient burden, as patient scans at multiple time points (MTPs) must be acquired. Dosimetry based on imaging at a single time point (STP) has continuously gained popularity. However, MTP protocols, used as a reference to judge the validity of STP
-
Dosimetry of [177Lu]Lu-PSMA–Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Zachary Ells, Tristan R. Grogan, Johannes Czernin, Magnus Dahlbom, Jeremie Calais
Novel theranostic approaches using radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have emerged for treating metastatic castration-resistant prostate cancer. The physical properties and commercial availability of 177Lu make it one of the most used radionuclides for radiopharmaceutical therapy (RPT). In this literature review, we aimed at comparing the dosimetry of the most
-
Design of a Fibroblast Activation Protein–Targeted Radiopharmaceutical Therapy with High Tumor–to–Healthy-Tissue Ratios J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Ramesh Mukkamala, Daniel J. Carlson, Nicholas Kaine Miller, Spencer D. Lindeman, Emily Renee Bowen, Pooja Tudi, Taylor Schleinkofer, Owen C. Booth, Abigail Cox, Madduri Srinivasarao, Philip S. Low
Because of upregulated expression on cancer-associated fibroblasts, fibroblast activation protein (FAP) has emerged as an attractive biomarker for the imaging and therapy of solid tumors. Although many FAP ligands have already been developed for radiopharmaceutical therapies (RPTs), most suffer from inadequate tumor uptake, insufficient tumor residence times, or off-target accumulation in healthy tissues
-
Synthesis of 64Cu-, 55Co-, and 68Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 German O. Fonseca Cabrera, Xinrui Ma, Wilson Lin, Tao Zhang, Weiling Zhao, Liqin Pan, Xiaomei Li, Todd E. Barnhart, Eduardo Aluicio-Sarduy, Huaifu Deng, Xuedan Wu, Kadalipura P. Rakesh, Zibo Li, Jonathan W. Engle, Zhanhong Wu
The development of theranostic radiotracers relies on their binding to specific molecular markers of a particular disease and the use of corresponding radiopharmaceutical pairs thereafter. This study reports the use of multiamine macrocyclic moieties (MAs), as linkers or chelators, in tracers targeting the neurotensin receptor-1 (NTSR-1). The goal is to achieve elevated tumor uptake, minimal background
-
Spleen Volume Reduction Is a Reliable and Independent Biomarker for Long-Term Risk of Leukopenia Development in Peptide Receptor Radionuclide Therapy J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Lisa Steinhelfer, Friederike Jungmann, Lukas Endrös, Patrick Wenzel, Bernhard Haller, Manuel Nickel, Eva Haneder, Fabian Geisler, Katharina Götze, Alexander von Werder, Matthias Eiber, Markus R. Makowski, Rickmer Braren, Fabian Lohöfer
177Lu-DOTATATE therapy is an effective treatment for advanced neuroendocrine tumors, despite its dose-limiting hematotoxicity. Herein, the significance of off-target splenic irradiation is unknown. Our study aims to identify predictive markers of peptide receptor radionuclide therapy–induced leukopenia. Methods: We retrospectively analyzed blood counts and imaging data of 88 patients with histologically
-
Interreader and Intrareader Reproducibility of 18F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Phillip H. Kuo, Giuseppe Esposito, Gary A. Ulaner, Don Yoo, Katherine Zukotynski, Gregory C. Ravizzini, Ross Penny, Matthew P. Miller, Albert Chau, Phillip Davis, Brian F. Chapin, David M. Schuster, on behalf of the SPOTLIGHT and LIGHTHOUSE study groups
Interreader and intrareader reproducibility of 18F-flotufolastat PET/CT scans in newly diagnosed and recurrent prostate cancer patients was assessed from masked image evaluations from two phase 3 studies. Methods: 18F-flotufolastat PET/CT images of newly diagnosed (n = 352) or recurrent (n = 389) patients were evaluated by 3 masked readers. Cohen was used to assess pairwise patient- and region-level
-
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 James P. Buteau, Louise Kostos, Ramin Alipour, Price Jackson, Lachlan McInstosh, Brittany Emmerson, Mohammad B. Haskali, Jing Xie, Elizabeth Medhurst, Rajeev Ravi, Brian D. Gonzalez, Heidi Fettke, Benjamin Blyth, Luc Furic, Katie Owen, Shahneen Sandhu, Declan G. Murphy, Arun A. Azad, Michael S. Hofman
[177Lu]Lu-PSMA is an effective class of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC); however, progression is inevitable. The limited durability of response may be partially explained by the presence of micrometastatic deposits, which are energy-sheltered and receive low absorbed radiation with 177Lu due to the approximately 0.7-mm mean pathlength. 161Tb has abundant
-
PET/CT-Based Absorbed Dose Maps in 90Y Selective Internal Radiation Therapy Correlate with Spatial Changes in Liver Function Derived from Dynamic MRI J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Zhonglin Lu, Daniel F. Polan, Lise Wei, Madhava P. Aryal, Kellen Fitzpatrick, Chang Wang, Kyle C. Cuneo, Joseph R. Evans, Molly E. Roseland, Joseph J. Gemmete, Jared A. Christensen, Baljendra S. Kapoor, Justin K. Mikell, Yue Cao, Greta S.P. Mok, Yuni K. Dewaraja
Functional liver parenchyma can be damaged from treatment of liver malignancies with 90Y selective internal radiation therapy (SIRT). Evaluating functional parenchymal changes and developing an absorbed dose (AD)–toxicity model can assist the clinical management of patients receiving SIRT. We aimed to determine whether there is a correlation between 90Y PET AD voxel maps and spatial changes in the
-
The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue, 68Ga-FAPI-46 PET Data, and Survival Data J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Christoph Oster, Lukas Kessler, Tobias Blau, Kathy Keyvani, Kim M. Pabst, Wolfgang P. Fendler, Pedro Fragoso Costa, Lazaros Lazaridis, Teresa Schmidt, Jonas Feldheim, Daniela Pierscianek, Hans Ulrich Schildhaus, Ulrich Sure, Yahya Ahmadipour, Christoph Kleinschnitz, Nika Guberina, Martin Stuschke, Cornelius Deuschl, Björn Scheffler, Ken Herrmann, Sied Kebir, Martin Glas
Despite their unique histologic features, gliosarcomas belong to the group of glioblastomas and are treated according to the same standards. Fibroblast activation protein (FAP) is a component of a tumor-specific subpopulation of fibroblasts that plays a critical role in tumor growth and invasion. Some case studies suggest an elevated expression of FAP in glioblastoma and a particularly strong expression
-
Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Duminduni Hewa Angappulige, Nimrod S. Barashi, Nicholas Pickersgill, Cody Weimholt, Jingqin Luo, Ghazal Shadmani, Ziad Tarcha, Sampanna Rayamajhi, Nupam P. Mahajan, Gerald L. Andriole, Barry A. Siegel, Eric H. Kim, Kiran Mahajan
Homeobox 13 (HOXB13) is an oncogenic transcription factor that directly regulates expression of folate hydrolase 1, which encodes prostate-specific membrane antigen (PSMA). HOXB13 is expressed in primary and metastatic prostate cancers (PCs) and promotes androgen-independent PC growth. Since HOXB13 promotes resistance to androgen receptor (AR)–targeted therapies and regulates the expression of folate
-
Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study) J Nucl. Med. (IF 9.1) Pub Date : 2024-08-01 Matteo Bauckneht, Francesco Lanfranchi, Domenico Albano, Luca Triggiani, Flavia Linguanti, Luca Urso, Rosario Mazzola, Alessio Rizzo, Elisa D’Angelo, Francesco Dondi, Eneida Mataj, Gloria Pedersoli, Elisabetta Maria Abenavoli, Luca Vaggelli, Beatrice Detti, Naima Ortolan, Antonio Malorgio, Alessia Guarneri, Federico Garrou, Matilde Fiorini, Serena Grimaldi, Pietro Ghedini, Giuseppe Carlo Iorio, Antonella
Metastasis-directed therapy (MDT) has been tested in clinical trials as a treatment option for oligorecurrent prostate cancer (PCa). However, there is an ongoing debate regarding the impact of using different imaging techniques interchangeably for defining lesions and guiding MDT within clinical trials. Methods: We retrospectively identified oligorecurrent PCa patients who had 5 or fewer nodal, bone